STSS SHARPS TECHNOLOGY INC

Sharps Regains Nasdaq Listing Compliance

Sharps Regains Nasdaq Listing Compliance

NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that on November 13, 2024, the Company was notified by the Nasdaq Stock Market (“Nasdaq”) that the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market, as set forth in Nasdaq Listing Rule 5550(a)(2) as of November 5, 2024.

The Company’s Chief Executive Officer Robert Hayes stated, “We are extremely pleased with our bid price compliance. We view our listing on Nasdaq to be extremely important to us as a Company as it offers the Company and its shareholders the best opportunity for the future. Further, we want to thank the shareholders for their support of the reverse split that supported Sharps regaining compliance.”

About Sharps Technology:

Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company’s product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. For additional information, please visit .

Forward-Looking Statements:

This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Investor Relations:

Dave Gentry

RedChip Companies, Inc.

1-800-RED-CHIP (733-2447)

Or 407-644-4256



EN
18/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SHARPS TECHNOLOGY INC

 PRESS RELEASE

Sharps Technology and BitGo Announce Collaboration to Advance Solana T...

Sharps Technology and BitGo Announce Collaboration to Advance Solana Treasury Strategy NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (“STSS” or the “Company”) (NASDAQ: STSS), a medical device company with a Solana (SOL) digital asset treasury strategy, and BitGo Bank & Trust, National Association (“BitGo”), the digital asset infrastructure company, today announced a strategic collaboration under which STSS will expand and further institutionalize its Solana treasury strategy through BitGo’s services. As part of this arrangement, STSS intends to utilize BitGo’s insti...

 PRESS RELEASE

Sharps Technology Reports Strong Solana Staking Income

Sharps Technology Reports Strong Solana Staking Income NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (“STSS” or the “Company”), a medical device company implementing a Solana-based digital asset treasury strategy, today issued an update on its treasury and recent operational highlights. Treasury Updates Staking: Since inception, STSS’s validator partners have generated ~7% gross annual percentage yield (APY) before fees, outperforming the Solana network average. Nearly all of the Company’s SOL holdings are currently staked.Balance Sheet: STSS continues to maintain ...

 PRESS RELEASE

Sharps Technology Strengthens Market Confidence with Advisor Lock-Up A...

Sharps Technology Strengthens Market Confidence with Advisor Lock-Up Agreement NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) today announced that it has entered into a 90-day lock-up agreement with SOL Markets (the “Strategic Advisor”), pursuant to which SOL Markets has agreed to restrict sales of its advisory warrants and any underlying shares. The lock-up reflects strong conviction in STSS’s execution roadmap and reinforces alignment between the parties. This comes after the company's recent announcement that its Board of Directors approved a share b...

 PRESS RELEASE

Sharps Technology and Coinbase Expand Relationship with Launch of Inst...

Sharps Technology and Coinbase Expand Relationship with Launch of Institutional-Grade Solana Validator NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (“STSS” or the “Company”) (NASDAQ: STSS), a medical device company implementing a Solana-based digital asset treasury strategy, today announced the expansion of its relationship with Coinbase Institutional, a leading provider of custody, prime brokerage, derivatives, staking, and trading services, through the launch of a jointly supported institutional-grade validator on the Solana network. The STSS Validator, operated ...

 PRESS RELEASE

Sharps Technology Reports Strong Growth in Q3 2025 as it Advances Exec...

Sharps Technology Reports Strong Growth in Q3 2025 as it Advances Execution of Treasury Strategy NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (“STSS” or the “Company”), a U.S.-based medical device sales and distribution platform that has adopted a Solana-based treasury strategy, today announced financial results for the third quarter ended September 30, 2025, and provided updates on the execution of its capital markets and digital asset initiatives. “The third quarter was transformative for Sharps Technology,” said Paul K. Danner, Executive Chairman. “Our adoption ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch